Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection Summary: The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection. Conditions: Hepatitis B Virus Infection Study type: INTERVENTIONAL Primary purpose: TREATMENT Phases: PHASE1 Enrollment: 48 (ESTIMATED) Status: RECRUITING Completion: 2027-09 (ESTIMATED)
ClinicalTrials.gov published a clinical update in Infectious Disease on 18 Mar 2026.
The item focuses on A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection.
Review the original article for the full source wording and details.